Avience Biomedicals Analysis IPO Details Future Prospects

Avience Biomedicals Limited is a healthcare diagnostics company with over 20 years of experience in molecular biotechnology and in-vitro diagnostics. The company is engaged in the manufacturing and supply of diagnostic kits, molecular testing products, and healthcare solutions, serving hospitals, laboratories, and healthcare providers across India through its research-driven and quality-focused operations.

Avience Biomedicals IPO will open for subscription on June 18, 2026, and close on June 22, 2026. The company plans to raise approximately ₹30.24 crore through a fresh issue at a price band of ₹196 to ₹208 per share. The IPO is scheduled to list on NSE on June 25, 2026, with the allotment expected on June 23, 2026.

Avience Biomedicals IPO Details

Avience Biomedicals IPO DATES

Avience Biomedicals IPO Dates

Financials of Avience Biomedicals

Strengths

• Strong growth in revenue and profitability.
• Operates in the healthcare and biomedical sector, which offers long-term growth opportunities.
• Healthy improvement in profit margins during FY2025.

Risks

• Relatively small-scale operations compared to larger healthcare companies.
• Business may be subject to regulatory and compliance requirements.
• Dependence on demand from healthcare and pharmaceutical sectors.

About Avience Biomedicals Limited

Avience Biomedicals Limited is a healthcare and diagnostics company with over 20 years of experience in molecular biotechnology, genomics, molecular markers, and in-vitro diagnostics (IVD). The company develops, manufactures, supplies, and distributes diagnostic products and healthcare solutions, focusing on innovative and affordable diagnostics for both urban and rural populations. It also partners with international healthcare technology companies to bring advanced diagnostic solutions to the Indian market.

Product Portfolio

• Dengue Diagnostic Kits
• Dengue NS1 Antigen Test Kits
• Malaria Rapid Test Kits (Pan/Pf)
• Malaria Rapid Test Kits (Pf/Pv)
• Typhoid IgG/IgM Antibody Test Kits
• Pregnancy Test Strips
• Pregnancy Test Cards
• COVID-19 Detection Kits
• COVID-19 RT-qPCR Assay Kits
• Syphilis Rapid Test Kits
• Viral Transport Medium (VTM)
• Molecular Diagnostic Products
• In-Vitro Diagnostic (IVD) Products
• Genomics and Molecular Biotechnology Solutions

The company is engaged in the development and manufacturing of diagnostic kits and molecular diagnostic products while maintaining a strong distribution network across India. Supported by an in-house research team, Avience continuously works on identifying new molecular markers and developing innovative diagnostic solutions for disease detection, risk assessment, and healthcare applications. It serves over 500 clients and has a presence across 120+ cities in India.

Avience Biomedicals IPO GMP Day 2

Check out the latest Avience Biomedicals IPO GMP (Grey Market Premium), Kostak rates, and Subject to Sauda updates. Avience Biomedicals IPO GMP has started trading in the grey market and is drawing attention from investors ahead of the public issue. Stay tuned for daily GMP movements and market sentiment indicators.

Avience Biomedicals IPO GMP touched a high of ₹85 on June 19, 2026, while the low stood at ₹40 on June 15, 2026. The SME IPO is scheduled to open on June 18, 2026, and aims to raise approximately ₹30.24 crore. The company has fixed the IPO price band at ₹196 to ₹208 per share, with a market lot size of 1,200 shares.

Avience Biomedicals IPO GMP Live Rates day by day.

Date	IPO GMP	GMP Trend	Gain
19 June	₹85		40.87%
18 June	₹75		36.06%
17 June	₹75		36.06%
16 June	₹70		33.65%
15 June	₹40		19.23%

Avience Biomedicals IPO Subscription Status – Day 2

FAQs

1. What is Avience Biomedicals IPO?

It is an NSE SME IPO through which the company plans to raise approximately ₹30.24 crore.

2. When will Avience Biomedicals IPO open?

The IPO will open on June 18, 2026, and close on June 22, 2026.

3. What is the price band of Avience Biomedicals IPO?

The price band is fixed at ₹196 to ₹208 per share.

4. What does Avience Biomedicals manufacture?

The company manufactures diagnostic kits, molecular testing products, and healthcare solutions.

5. What are the key products of Avience Biomedicals?

Its products include dengue, malaria, COVID-19, pregnancy, and syphilis diagnostic test kits.

6. How was the company’s financial performance in FY2025?

The company reported revenue of ₹45.97 crore and profit of ₹7.23 crore.

7. What are the strengths of Avience Biomedicals?

Strong revenue growth, improving profitability, and a diversified diagnostic product portfolio.

8. What are the major risks of the IPO?

Regulatory risks, industry competition, and dependence on healthcare sector demand.

9. Is Avience Biomedicals IPO suitable for long-term investors?

Based on its growth and financial performance, it may be suitable for long-term investors.

10. What are the future prospects of Avience Biomedicals?

Growing demand for diagnostic testing and healthcare solutions could support future growth.